4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age50+
Sponsor4D Molecular Therapeutics
About this trial
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Eligibility criteria
Qualifiers
50 years of age
≥50 years of age
Diagnosed with CNV secondary to AMD (confirmed by reading center)
Study eye amenable to IVT injection
Disqualifiers
None
Trial design
Treatments tested in this trial
- 4D-150 IVT
- Aflibercept IVT
Treatment groups
215 Participants
are divided into 10 treatment groups10
Treatment groupsSee each treatment group below.
Locations
25Puerto Rico
Emanuelli Research and Development Center, LLC00612, AreciboPuerto Rico, Puerto Rico
United States
Arizona
Barnet Delaney Perkins Eye Center85016, Phoenix United States
California
California Retina Consultants93036, Oxnard United States
Retinal Consultants Medical Group95841, Sacramento United States
Sponsors and collaborators
4D Molecular Therapeutics
Lead sponsor
Source ClinicalTrials.gov